Celcuity Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Celcuity Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($177.04M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($111.78M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($63.78M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($40.37M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($29.61M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($9.47M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($7.36M) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($7.48M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($6.25M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($3.31M) | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($172.19M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($113.27M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($66.23M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($39.39M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($28.36M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($9.56M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($7.81M) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($7.93M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($5.95M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($3.33M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.00M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $104.20M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $60.59M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $35.29M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $25.76M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $7.68M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $6.27M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $6.33M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $4.98M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.06M | Mar 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($153.28M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($83.47M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($53.81M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($36.01M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($20.31M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($7.15M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($6.00M) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($6.08M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($4.95M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($2.89M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $249.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $250.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $97.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $158.8K | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $81.9K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $89.4K | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($380.2K) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $629.6K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $239.8K | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $40.9K | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $466.56M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $245.12M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $191.22M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $175.70M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $85.91M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $12.96M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $20.28M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $26.03M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $31.97M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.06M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $366.00M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $129.50M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $51.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $41.93M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $17.20M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.25M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $983.2K | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $682.2K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $578.1K | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $445.4K | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.56M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $115.62M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $139.77M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $133.77M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $68.71M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $11.70M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $19.30M | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | $25.35M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $31.39M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $5.61M | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($448.90M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($271.86M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($160.08M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($96.30M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($55.93M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($26.32M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($16.85M) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($9.49M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($2.01M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($8.33M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.70M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $22.52M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $30.66M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $24.57M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $84.29M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $11.64M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $18.74M | Feb 16, 2021 |
| FY2020 | Dec 31, 2018 | $15.94M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $2.69M | Mar 13, 2020 |
| FY2017 | Dec 31, 2016 | $5.86M | Mar 15, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.55M | Mar 26, 2026 |
| FY2024 | Dec 31, 2024 | $105.09M | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $37.57M | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | $35.76M | Mar 23, 2023 |
| FY2021 | Dec 31, 2021 | $15.98M | Mar 23, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 27, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.24M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 37.14M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 25.51M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 21.67M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 14.92M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 10.30M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | 10.25M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | 10.19M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 10.09M | Mar 1, 2019 |
| FY2020 | Sep 22, 2017 | 10.08M | Feb 16, 2021 |